Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma

Kevin C. Miller, John P. Marinelli, Jamie Van Gompel, Michael J. Link, Jeffrey R. Janus, Robert L. Foote, Katharine A. Price, Joaquin Garcia, Michael Rivera, Ashish Chintakuntlawar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Past research established that surgery plus adjuvant radiotherapy (S + AR) improves overall survival (OS) in esthesioneuroblastoma (ENB). However, it is unknown if the addition of adjuvant chemotherapy (AC) further improves survival. The primary objective of this study was to compare survival among patients treated with S + AR alone to patients who underwent S + AR + AC. Methods: Retrospective review of patient records. Results: Thirty-eight patients met inclusion criteria for either S + AR or S + AR + AC treatment groups. The S + AR + AC group contained more patients with Kadish stage D disease, dural invasion, and positive histologic margins postsurgery. All S + AR + AC patients received platinum-based regimens, combined with etoposide in 67%. OS and recurrence-free survival did not differ between the two groups, even when restricting the analysis to patients with Kadish stages B and C disease. Conclusion: Patients who received platinum-based AC did not exhibit improved survival compared to S + AR alone. Further investigation, preferably prospective, into the optimal use of systemic therapy in ENB is warranted.

Original languageEnglish (US)
JournalHead and Neck
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Olfactory Esthesioneuroblastoma
Adjuvant Radiotherapy
Adjuvant Chemotherapy
Survival
Therapeutics
Platinum
Etoposide
Recurrence

Keywords

  • adjuvant
  • chemotherapy
  • esthesioneuroblastoma
  • olfactory neuroblastoma
  • survival

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma. / Miller, Kevin C.; Marinelli, John P.; Van Gompel, Jamie; Link, Michael J.; Janus, Jeffrey R.; Foote, Robert L.; Price, Katharine A.; Garcia, Joaquin; Rivera, Michael; Chintakuntlawar, Ashish.

In: Head and Neck, 01.01.2018.

Research output: Contribution to journalArticle

Miller, Kevin C. ; Marinelli, John P. ; Van Gompel, Jamie ; Link, Michael J. ; Janus, Jeffrey R. ; Foote, Robert L. ; Price, Katharine A. ; Garcia, Joaquin ; Rivera, Michael ; Chintakuntlawar, Ashish. / Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma. In: Head and Neck. 2018.
@article{3f15ba6968ea41228acf9e2cfe850f7e,
title = "Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma",
abstract = "Background: Past research established that surgery plus adjuvant radiotherapy (S + AR) improves overall survival (OS) in esthesioneuroblastoma (ENB). However, it is unknown if the addition of adjuvant chemotherapy (AC) further improves survival. The primary objective of this study was to compare survival among patients treated with S + AR alone to patients who underwent S + AR + AC. Methods: Retrospective review of patient records. Results: Thirty-eight patients met inclusion criteria for either S + AR or S + AR + AC treatment groups. The S + AR + AC group contained more patients with Kadish stage D disease, dural invasion, and positive histologic margins postsurgery. All S + AR + AC patients received platinum-based regimens, combined with etoposide in 67{\%}. OS and recurrence-free survival did not differ between the two groups, even when restricting the analysis to patients with Kadish stages B and C disease. Conclusion: Patients who received platinum-based AC did not exhibit improved survival compared to S + AR alone. Further investigation, preferably prospective, into the optimal use of systemic therapy in ENB is warranted.",
keywords = "adjuvant, chemotherapy, esthesioneuroblastoma, olfactory neuroblastoma, survival",
author = "Miller, {Kevin C.} and Marinelli, {John P.} and {Van Gompel}, Jamie and Link, {Michael J.} and Janus, {Jeffrey R.} and Foote, {Robert L.} and Price, {Katharine A.} and Joaquin Garcia and Michael Rivera and Ashish Chintakuntlawar",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/hed.25558",
language = "English (US)",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma

AU - Miller, Kevin C.

AU - Marinelli, John P.

AU - Van Gompel, Jamie

AU - Link, Michael J.

AU - Janus, Jeffrey R.

AU - Foote, Robert L.

AU - Price, Katharine A.

AU - Garcia, Joaquin

AU - Rivera, Michael

AU - Chintakuntlawar, Ashish

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Past research established that surgery plus adjuvant radiotherapy (S + AR) improves overall survival (OS) in esthesioneuroblastoma (ENB). However, it is unknown if the addition of adjuvant chemotherapy (AC) further improves survival. The primary objective of this study was to compare survival among patients treated with S + AR alone to patients who underwent S + AR + AC. Methods: Retrospective review of patient records. Results: Thirty-eight patients met inclusion criteria for either S + AR or S + AR + AC treatment groups. The S + AR + AC group contained more patients with Kadish stage D disease, dural invasion, and positive histologic margins postsurgery. All S + AR + AC patients received platinum-based regimens, combined with etoposide in 67%. OS and recurrence-free survival did not differ between the two groups, even when restricting the analysis to patients with Kadish stages B and C disease. Conclusion: Patients who received platinum-based AC did not exhibit improved survival compared to S + AR alone. Further investigation, preferably prospective, into the optimal use of systemic therapy in ENB is warranted.

AB - Background: Past research established that surgery plus adjuvant radiotherapy (S + AR) improves overall survival (OS) in esthesioneuroblastoma (ENB). However, it is unknown if the addition of adjuvant chemotherapy (AC) further improves survival. The primary objective of this study was to compare survival among patients treated with S + AR alone to patients who underwent S + AR + AC. Methods: Retrospective review of patient records. Results: Thirty-eight patients met inclusion criteria for either S + AR or S + AR + AC treatment groups. The S + AR + AC group contained more patients with Kadish stage D disease, dural invasion, and positive histologic margins postsurgery. All S + AR + AC patients received platinum-based regimens, combined with etoposide in 67%. OS and recurrence-free survival did not differ between the two groups, even when restricting the analysis to patients with Kadish stages B and C disease. Conclusion: Patients who received platinum-based AC did not exhibit improved survival compared to S + AR alone. Further investigation, preferably prospective, into the optimal use of systemic therapy in ENB is warranted.

KW - adjuvant

KW - chemotherapy

KW - esthesioneuroblastoma

KW - olfactory neuroblastoma

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85058195370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058195370&partnerID=8YFLogxK

U2 - 10.1002/hed.25558

DO - 10.1002/hed.25558

M3 - Article

C2 - 30536472

AN - SCOPUS:85058195370

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

ER -